Compass Therapeutics (CMPX) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Invivyd (IVVD) has outperformed Compass Therapeutics (CMPX) over the past year, losing 55.3% versus a loss of 71.7%. Over five years, CMPX leads with a -68.2% price change compared with -97.8% for IVVD. Invivyd is the larger company by market cap ($214.8 million vs $183.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | IVVD |
|---|---|---|
| Share price | $1.02 | $0.7286 |
| Market cap | $183.69M | $214.76M |
| 1-day change | +2.19% | -9.65% |
| YTD return | -81.01% | -70.50% |
| 1-year return | -71.75% | -55.30% |
| 5-year return | -68.22% | -97.75% |
| EPS (TTM) | $-0.40 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.88 | $3.07 |
| 52-week low | $0.829 | $0.528 |
| Distance from 52-week high | -85.17% | -76.27% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +434.31% | +1272.50% |
| Average volume | 4.08M | 4.70M |
| Shares outstanding | 180.09M | 294.76M |
| Employees | 39 | 122 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IVVD has outperformed CMPX by 16.4 percentage points over the past year.
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Healthcare · Biotechnology · 39 employees
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Healthcare · Biotechnology · 122 employees
CMPX vs IVVD FAQ
Which is bigger, Compass Therapeutics or Invivyd?
Invivyd (IVVD) is larger, with a market capitalization of $214.76M compared with $183.69M for Compass Therapeutics (CMPX).
Which stock has performed better over the past year, CMPX or IVVD?
IVVD returned -55.30% over the past 12 months, compared with -71.75% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Invivyd in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.